{"symbol":"GILD","fiscalQuarter":"Q4-2025","reportDate":"2026-02-10","reportTime":"AMC","status":"reported","company":{"name":"Gilead Sciences, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/GILD/earnings/Q4-2025","postBrief":{"headline":"Gilead Sciences Beats on EPS, Stock Down 2.93%","keyNumbers":[{"metric":"EPS","actual":"$1.86","expected":"N/A","surprise":"+1.92%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing efforts to enhance product pipeline.","They expressed confidence in long-term growth despite current market challenges."],"summary":"Overall, management conveyed a sense of cautious optimism regarding future developments. They emphasized their commitment to innovation and addressing market needs."},"guidanceChanges":{"summary":"No forward guidance was provided during this earnings call.","changes":[]},"whatItMeans":"Gilead Sciences reported a slight earnings beat on EPS, but the stock fell by nearly 3% following the announcement. Investors may be concerned about the lack of revenue data and forward guidance, which could indicate uncertainty about future performance. The stock reaction suggests that market sentiment remains cautious despite the positive EPS surprise.","metaDescription":"Gilead Sciences (GILD) Q4 2025 earnings: EPS beat by 1.92%. Stock down 2.93%. Full breakdown."}}